Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20642400 | 0.79 | P2RX3 (0.35) | P2RX3P2RX2TAAR1 | |
| SCHEMBL18068013 | 0.78 | P2RX3 (0.35) | P2RX3P2RX2GRIN2BRXRAGRIN1 | |
| SCHEMBL20642318 | 0.76 | NOS3 (0.32) | P2RX3P2RX2GRIN2BKCNH2 | |
| SCHEMBL24759678 | 0.75 | NOS3 (0.39) | P2RX3P2RX2GRIN2BGRIN1 | |
| SCHEMBL21076469 | 0.74 | — | — | |
| SCHEMBL18791405 | 0.74 | NOS3 (0.32) | — | |
| SCHEMBL19508069 | 0.73 | P2RX3 (0.35) | P2RX3P2RX2 | |
| SCHEMBL21076527 | 0.73 | NOS3 (0.35) | — | |
| SCHEMBL23231054 | 0.72 | NOS3 (0.41) | — | |
| SCHEMBL12749936 | 0.70 | NOS3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | P2RX3 32/4885P2RX2 27/4885GRIN2B 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.